Different Genes Active in Cancer Patients of Different Races
High Mutation Frequency Does Not Predict Poor Outcome in Certain Patient Cohorts
UK Biotechs Present Novel Technologies at BioTrinity 2017
Biotechnology Rolls on Despite Brexit Uncertainty
Avoiding Costly Errors in Bioassay Development
Developers Have a Range of Options When Optimizing Bioassays for Biologics
Screening Innovations and 3D Cell Culture Assay Developments
Showcased at ELRIG
New Tech Aids Drug Discovery
For full access to this article login to GEN Select now.
Norway's Oncology Efforts Are Coalescing
The Oslo Cancer Cluster Is at the Heart of a Burgeoning Movement
- Most biotech companies in Norway are focused upon oncology, and 80% of the nation’s cancer research is located in or around the capital. Therefore, the formation of the Oslo Cancer Cluster (OCC), a partnership between industry, research institutions, government, and the Norwegian Cancer Society is a logical development. ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.